Navigation Links
ALS Research Gets a $4.1 Million Boost from CVS/pharmacy Fundraising Campaign

WOONSOCKET, R.I., Oct. 1 /PRNewswire/ -- In just 21 days, CVS/pharmacy's ninth annual in-store fundraising campaign to support the fight against amyotrophic lateral sclerosis (ALS) brought in $4.1 million. The funds raised by the campaign will be donated to the Boston-based ALS Therapy Alliance (ATA) to support the funding of new clinical research aimed at developing new therapies for ALS patients and focused on the ultimate goal of finding a cure for ALS. This donation brings the total amount raised by CVS/pharmacy colleagues and customers for ALS research over the last nine years to more than $23 million.



For people like Treg Charlton, a 44-year-old CVS Caremark colleague who was diagnosed with ALS in March, every single $1 donation for ALS research means getting one step closer to finding a treatment or cure for this devastating disease.

Charlton, a husband and father of two young daughters, decided shortly after being diagnosed that he wasn't going to sit on the sidelines while ALS began causing damage to his body. He served as this year's honorary co-chair of the CVS/pharmacy Researching a Cure campaign and plans to stay active in advocating for funding for ALS research.

"It's the challenge of a lifetime, but also a tremendous opportunity to socialize the importance of pushing forward with ALS research to finally discover a cure for it, to deal with the disease in a positive manner and to share my love of life and my optimism for finding a cure, with others," Charlton said.

ALS, or amyotrophic lateral sclerosis, is a disorder in which there is progressive degeneration of motor nerves in the brain and spinal cord leading to paralysis and death, typically within three to five years. There is no known cause or cure for ALS, which affects 25,000 Americans, with 5,000 new cases diagnosed each year.

Jon Roberts, executive vice president of CVS Caremark and co-chair for the last nine years of CVS/pharmacy's Researching a Cure campaign, said, "It is the courage and determination of people like Treg who put a face to this debilitating disease, that continue to motivate CVS/pharmacy, its colleagues and its customers to raise funds for ALS research. Having lost a loved one myself to ALS, it is tremendously gratifying to see the success of this year's campaign and to know that the funds raised are being applied to research conducted by the ALS Therapy Alliance."

"The ALS Therapy Alliance board members are profoundly grateful to CVS/pharmacy for its ALS fundraising campaign as the results continue to have a significant impact on research," said Robert Brown, Jr., D. Phil, M.D., Chair of the Dept. of Neurology at University of Massachusetts Medical School.

Dr. Brown added, "By working with outstanding scientists at multiple centers around the world, we have facilitated trials of therapy in ALS, accelerated the identification of new ALS genes, advanced studies of the role of RNA pathology in ALS, pursued studies of stem cells as ALS research tools and investigated groundbreaking methodologies for silencing genes that make toxic poisons or toxic proteins that lead to neurodegeneration.  We have also supported several ALS colloquia that bring together outstanding scientists from around the world.  Only with continued funding can we continue this progress." 

The official check presentation of the $4.1 million raised by this year's CVS/pharmacy Researching a Cure campaign will take place prior to the Boston Red Sox versus Yankees game at Fenway Park this evening. Additionally, Charlton, accompanied by his wife Dianne and their daughters Audrey and Mia, will throw out a ceremonial first pitch to raise awareness about the importance of funding ALS research in order to find a cure for the disease.

About the ALS Therapy AllianceThe ALS Therapy Alliance (ATA) was founded in 2000 to provide a vehicle for a diverse group of scientists and clinicians to coordinate research related to ALS. The scientists involved in the ATA are affiliated with some of the best universities and medical centers in the greater Boston area, including Massachusetts General Hospital, Harvard Medical School, Massachusetts Institute of Technology, Harvard College, Brigham and Women's Hospital, Beth Israel Deaconess Hospital, Boston University and the University of Massachusetts. CVS Caremark is the largest corporate donor to the ALS Therapy Alliance.

About CVS/pharmacyCVS/pharmacy, the retail division of CVS Caremark Corporation (NYSE: CVS), is America's leading retail pharmacy with more than 7,100 CVS/pharmacy and Longs Drug stores. CVS/pharmacy is committed to improving the lives of those we serve by making innovative and high-quality health and pharmacy services safe, affordable and easy to access, both in its stores and online at General information about CVS/pharmacy and CVS Caremark is available at Leach Carvelli(add)ventures401-453-4748401-572-4115 (cell)gcarvelli@addventures.comJoanne DwyerCVS/

SOURCE CVS/pharmacy
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HHS Awards $473 Million in Patient-Centered Outcomes Research Funding
2. While Ethicon Endo-Surgery and Allergan Remain Front-Runners in the $41 Million Gastric Band Market, Other Competitors Battle for Third Place, According to Millennium Research Group
3. New Manhattan Research Report Explores the Growing Consumer Demand for Online Health Video and How Pharma Marketers Can Leverage this Format
4. The Japanese Cancer Association and Debiopharm Group(TM) Present the JCA-Mauvernay Award to Dr Ogawa and Prof. Maeda for Their Outstanding Oncology Research
5. National Pharmaceutical Council Comments on Patient-Centered Outcomes Research Institute Board of Governors
6. Latin American Aortic Stent Graft Market to Reach Over $150 Million by 2015, According to Millennium Research Group
7. Mayo Clinic Research on SurgiCount To Be Presented at Conferences
8. Biodel Reports Research Progress in Poster Session on Short-Acting Insulins at 46th EASD Annual Meeting
9. Special Issue of PharmacoEconomics to Focus on Comparative Effectiveness Research
10. Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India
11. CulGenex™ by Hardy Diagnostics Assists Medical Researchers!
Post Your Comments:
(Date:11/30/2015)... -- Booth #4303 – The Imaging Components business of Varian ... array of products in a new booth (#4303) at the ... America in Chicago this ... components "At the Heart of Imaging." Products will include a ... Claymount brand, and computer-aided diagnostic software from MeVis as well ...
(Date:11/30/2015)... -- Hanger, Inc. (NYSE: HGR ) (the "Company") today ... its previously announced consent solicitation (as amended and restated, ... amount 7⅛% Senior Notes due 2018 (the "Notes") to ... pursuant to the Consent Solicitation, (ii) the proposed increased ... date of the Consent Solicitation.    ...
(Date:11/30/2015)... , Nov. 30, 2015   VolitionRx Limited (NYSE ... diagnostic tests for a broad range of cancer types and ... LD Micro Conference, which will be held December 1 - 3 ... from VolitionRx will be David Kratochvil , Chief Financial ... of Investor Relations. ® blood-based tests for ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... It’s inevitable that everyone ... member, close friend, or animal pass away, death lives among us. It is your ... Coming from a family of 11 children, author T Sky understands that she may ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announce the speakers for “Value-Based Payer-Provider Partnerships: Three Case Studies,” an upcoming ... value-based care arrangements: Essentia Health and UCare, MissionPoint Health Partners, and Intel ...
(Date:11/30/2015)... IL (PRWEB) , ... November 30, 2015 , ... The ... an emerging pharmaceutical company. Because it is so important to this key industry segment, ... Factors in your IND Filing” on December 4th at 11am EST. , Federal law ...
(Date:11/30/2015)... ... November 30, 2015 , ... Insightra Medical, Inc. ... Surgical Mesh technology for soft tissue repair in the US via Insightra’s national ... resorbable surgical mesh intended to support and reinforce soft tissue for 6-9 months ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... & Laser Center is one of a select few plastic surgeons in the ... non-surgical fat removal. , SculpSure™ is the world’s first heat-induced laser treatment for ...
Breaking Medicine News(10 mins):